EcoDrugPlus

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSDORG00000030173
Gene Symbol: NFE2L2
4 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSDORG00000001148
Gene Symbol: NR1H2
3 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSDORG00000007747
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSDORG00000001224
Gene Symbol: NR1H4
4 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSDORG00000024724
Gene Symbol: NR3C1
2 Cross references
280 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSDORG00000016701
Gene Symbol: NR3C2
4 Cross references
214 Possible Orthologues:

Nucleophosmin 1

Ensembl ID : ENSDORG00000028337
Gene Symbol: NPM1
2 Cross references
291 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDORG00000026607
Gene Symbol: NOD2
4 Cross references
167 Possible Orthologues:

Opioid Receptor Delta 1

Ensembl ID : ENSDORG00000015419
Gene Symbol: OPRD1
3 Cross references
254 Possible Orthologues:

Opioid Receptor Kappa 1

Ensembl ID : ENSDORG00000009506
Gene Symbol: OPRK1
4 Cross references
264 Possible Orthologues:

Opioid Receptor Mu 1

Ensembl ID : ENSDORG00000002315
Gene Symbol: OPRM1
3 Cross references
215 Possible Orthologues:

Opioid Related Nociceptin Receptor 1

Ensembl ID : ENSDORG00000010774
Gene Symbol: OPRL1
4 Cross references
202 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).